PD-L1 Biomarkers News and reporting on PD-L1 biomarkers. Dec 22, 2022 Gilead Sciences, Arcus Biosciences Tout Domvanalimab NSCLC Data as Good News for Anti-TIGIT Approach Premium Nov 29, 2022 Genentech to Withdraw First-Line Tecentriq Bladder Cancer Indication Nov 28, 2022 NICE Recommends BMS's Opdivo Plus Chemo for HER2-Negative, PD-L1-Positive Gastric Cancer Nov 17, 2022 Biomarker Predicts Immunotherapy Benefit in Head and Neck Cancer but Commercial Path Unclear Premium Oct 26, 2022 Bristol Myers Squibb Turns in Strong Q3 Opdualag Sales, Growth in CAR T Products Premium Oct 14, 2022 Nucleai Hopes to Engage Pharma on Next-Gen Immunotherapies With Proof-of-Concept AI-Based Biomarker Premium Sep 28, 2022 Cofactor Genomics RNA-seq Assay Outperforms PD-L1 IHC to Predict Immunotherapy Responders Premium Sep 16, 2022 BMS Combo Immunotherapy Opdualag Approved in Europe for Biomarker-Defined Melanoma Patients Sep 11, 2022 PD-L1 Test Comparison Finds Varying Ability to ID Bladder Cancer Patients Who Benefit From Tecentriq Sep 10, 2022 BMS Combo Drug Opdualag Effective in Neoadjuvant NSCLC, But Maybe No Better Than Opdivo Alone Premium Aug 26, 2022 Melanoma Docs Resurrect PD-L1 Debate as CHMP, FDA Diverge on Opdualag Label Premium Aug 24, 2022 Roche Gets Expanded CE Mark for Ventana PD-L1 Assay to ID NSCLC Patients for Tecentriq Jul 28, 2022 Merck's Keytruda Q2 Sales Grow 26 Percent; Firm Considers Future Impact of Medicare Price Setting Premium Jul 22, 2022 Bristol Myers Squibb's Opdualag Gets EMA CHMP Recommendation for Biomarker-Selected Melanoma Jul 6, 2022 Zenith Epigenetics to Explore BET Inhibitor Combinations in Multiple NCI-Sponsored Trials Jun 4, 2022 FDA Investigators Share Insights on First-Line Immunotherapy Regimens in NSCLC May 25, 2022 NICE Recommends Keytruda, Chemo Combo for Advanced TNBC, Narrows PD-L1 Expression Threshold May 18, 2022 City of Hope, Imugene Begin Trial of Oncolytic Virus in Advanced Solid Cancers May 16, 2022 BMS's Opdivo, Yervoy Combo Fails to Improve Overall Survival Versus Chemo in Bladder Cancer Trial May 13, 2022 NICE Recommends AstraZeneca's Imfinzi for PD-L1-Positive NSCLC Load More Breaking News Ratio Therapeutics Raises $20M in Series A Financing Guardant Health, AnHeart Tx to Develop Blood- and Tissue-Based CDx for NSCLC Drug Ellipses Pharma Cleared by FDA to Open Phase I/II AML Trial Survey Reveals Changing Genetic Testing Patterns, Persistent Disparities in Precision Oncology Amgen's Lumakras Sales Increased 58 Percent in Q4 2022 Coeptis Therapeutics, University of Pittsburgh Studying SNAP-CAR Therapy in HER2-Positive Cancers
